BioXcel Therapeutics (BioXcel Therapeutics) Accounts Receivable : $0.07 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. BioXcel Therapeutics's accounts receivables for the quarter that ended in Dec. 2023 was $0.07 Mil.

Accounts receivable can be measured by Days Sales Outstanding. BioXcel Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 17.23.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. BioXcel Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-2.14.

BioXcel Therapeutics Accounts Receivable Historical Data

The historical data trend for BioXcel Therapeutics's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioXcel Therapeutics Accounts Receivable Chart

BioXcel Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Receivable

Get a 7-Day Free Trial

0.25

0.07

BioXcel Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															0.25	0.28	0.43	0.74	0.07

BioXcel Therapeutics Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

BioXcel Therapeutics Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

BioXcel Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.071	/	0.376	*	91
=	17.23

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), BioXcel Therapeutics's accounts receivable are only considered to be worth 75% of book value:

BioXcel Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(65.221	+	0.75 * 0.071	+	0.5 * 1.991	-	130.21
-	0	-	0)	/	29.93
=	-2.14

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

BioXcel Therapeutics Accounts Receivable Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics (BioXcel Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

BX2:Germany

Address

555 Long Wharf Drive, 12th Floor, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Executives

Vimal Mehta	director, officer: CEO, President, Secretary	780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Richard I Steinhart	officer: Chief Financial Officer	125 ELM STREET, NEW CANAAN CT 06840
Javier Rodriguez	officer: SEE REMARKS	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Krishnan Nandabalan	director, 10 percent owner	228 VILLAGE POND ROAD, GUILFORD CT 06437
Akrati Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello	10 percent owner	10 TEMPLETON ROAD, WALLINGFORD CT 06492
Krunal Dilip Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Alka Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Pardeep Kumar Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Anita Jain	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437